CathVision, a Copenhagen, Denmark-based medical technology company developing electrophysiology solutions, raised $9M in funding.
The round brought the total amount to $30M.
The company intends to use the funds to advance commercial operations driving adoption of the ECGenius™ System, its EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with levels of automated analysis during cardiac ablation procedures. This includes expansion of its sales team and U.S. presence, and further development of the CARDIALYTICS™ suite of AI analytics.
Led by CEO Mads Matthiesen, CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System.
The system includes a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. It received FDA 510(k) clearance in May 2022 and is currently available.
Founded in 2013, the company has a U.S. office in Minnesota.
FinSMEs
18/07/2023